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Background: Atheroprotective high-density lipoprotein cholesterol (HDL-C) and its 
major structural protein, apolipoprotein Al (apoA1) may inhibit plaque expansion by 
mediating reverse cholesterol transport. However, whether statin-induced increased the 
level of HDL-C affects the volume of coronary atherosclerotic plaque is not fully under- 
stood. Therefore we investigated the relationship between HDL-C levels and plaque 
appearances with statin therapy. 
Methods and Results: 50 patients undergoing percutaneous coronary intervention (PCI) 
were studied with Intravascular ultrasound (IVUS) after PCI and at a 6-month follow-up 
period of treatment with pravastatin. In non-dilated matched coronary segments, volu- 
metric analyses were performed with 3.dimensional (3-D) IVUS system. After 6months 
therapy, pravastatin significantly reduced plasma levels of total cholesterol and low-den- 
sity lipoprotein cholesterol (LDL-C), and oxidized-LDL by 24, 25, and 15%, respectively, 
and increased HDL-C and apoA1 levels by 10.2 and 9.2% (p<O.OOl vs. baseline levels 
for all variables). BD-IVUS examination revealed that plaque volume was significantly 
decreased (baseline vs. 6 months: 46.4*30.3 vs. 39.0+26.2mm3, pcO.OOOl), whereas no 
significant differences in lumen and vessel volume are observed (64.9A39.7 vs. 
69.0*37.1mm3, p=O.lO; 113.4i63.7 vs. 106.0~57.4mn?, ~30.13). Furthermore, % 
changes in plaque volume were inversely correlated with those in plasma levels of HDL- 
C (r=-0.54, pcO.0001) and apoA1 (r=-0.43, pcO.O5), but not with those in the levels of 
total cholesterol (r=0.23, p=O.l2) and LDL-C (rz0.24, p=O.25), and oxidized-LDL (r=0.12, 
p=0.35). 
Conclusions: Our results demonstrated that pravastatin-induced increased the levels of 
HDL-C and apoA1 were associated with a comparable, significant reduction in the 
amount of plaque volume. We suggest that pravastatin therapy even at a 6-month follow 
up may enhance the role of HDL-C containing apoA-I in reverse cholesterol transport. 
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Medicine, Philadelphia, PA 
Background: Retrospective clinical data Indicate that HMG-CoA reductase inhibitors 
(statins) limit calcification in atherosclerotic coronary arteries and aortic valves. However 
the mechanism of action of statins in prevention of calcification is unknownMethods: 
We evaluated the effects of statins on cardiac valve calcificatmn in vitro using a previ- 
ously validated cell culture model of valve calcification. Porcine aortic valve interstitial 
cells were incubated in varying concentrations of simvastatin and pravastatln (0 1, 0.3. 
and 0.6 FM) to determine if these drugs inhibit calcific nodule formabon. Mevalonate (1 .O 
FM), metabolite of HMG-CoA reductase, was given to determine if the mechanism of 
inhibition involves the cholesterol biosynthetic pathway. Alkaline phosphatase activity, a 
marker of osteoblastlc differenbation, was measured in cell lysates. Results: Simvastatin 
and pravastatin inhibited calcific nodule formation in a dose-dependent manner and there 
was a partial reversal of effect with mevalonate (Figure). Alkaline phosphatase activity 
was reduced with statins, also in a dose-dependent manner. Conclusions: Statins drugs 
inhibit valve calcification partially through inhibition of cholesterol biosynthetic pathway 
and alkaline phosphatase. These data provide further evidence that statins will prove 
useful therapy for calcific cardiac valve disease 
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Introduction: Exercise exerts a pro-angiogenic effect by mechanisms which are not fully 
understood. Circulating endothelial progenitor cells (EPCs) have been shown to partici- 
pate in formation of new blood vessels. Since exercise acutely increases circulating lym- 
phocyte number, we investigated whether exercise may act in a pro-angiogenic manner 
wa increases in circulating EPCs. 
Methods: Subjects without evidence of coronary artery disease were exercised on a 
treadmill or bicycle to a mean of 92*2 % of their predicted maximum heart rate. Blood 
samples were obtained before and immediately after exercise. Whole blood was ana- 
lyzed for the stem / progenitor cell marker AC133 (n=6) by flow cytometry. EPCs were 
isolated as previously described by plating the mononuclear cell fraction on a fibronectin- 
coated plate m EGM-P-MV media (ClonetIcs) and discarding non-adherent cells (n=9). 
Adherent EPCs were counted, and conditioned media was collected on a subset of the 
cell samples (n=5). The conditioned media was assayed for the angiogenic hepatocyte 
growth factor (HGF), which IS not present in EGM-2.MV media. Statistical analysis was 
performed using a paired t-test comparing pre- and post-exercise values. 
Results: Dynamic exercise significantly Increased the number of circulating AC133+ 
cells from 1307k.332 cells/ml to 22722511 cells/ml of blood (p=O.O22). Exercise also 
increased the number of adherent EPCs isolated from peripheral blood, by plating and 
culturing, from 7694+2586 cells/ml of blood to 19656+5716 cells/ml (p=O.O06). The 
adherent cells were equipotent m their ability to secrete HGF before and after exercise 
(44.2tl3.3 ng/106 cells vs 35.1 e7.0 ng/lOs cells, p=not significant). 
Conclusions Exercise can acutely increase the number of circulating cells which 
express the stem I progenitor cell marker AC133 as well as the EPC cells Isolated by 
plating and culturing. The latter cells also secrete the angiogenic growth factor HGF, 
which may in turn mediate some of their angiogenic effects. These findings suggest a 
novel means by which exercise may be cardmprotective. Furthermore, these results may 
also contribute to our understanding of stem and progenitor cell mob!lization. 
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Background: hksemnchymal stem cell (MSC) adminlstration has shown promising 
results for treatment of LV diysfunction in the acute Ml model. We sought to evaluate the 
safety and efficacy of intramyocardial delivery of allogeneic MSCs in a chronic ischemia 
model.. 
Methods: Allogeneic MSCs of dogs were cultured, expanded in vitro. Twelve healthy 
adult dogs were submitted to ameroid constnctor implant (proximal LAD) with diagonal 
branch ligation. Surgical intramyocardial injections (IMI) of 100x10s MSCs (10 ml) were 
distributed over 20 sites in the anterior wall in 6 animals(MSC group). The control group 
(n=6) received saline injectlons in the same manner. Left coronary angiography was per- 
formed immediately before IMI and 30 days after to certify ameroid constriction and 
assess anatomy. Echo was performed at baseline before ameroid implant and at 30 days 
(immediately before IMI) and at 30 days after IMI to assess LV ejection fraction (EF). 
Results: IMls were performed wcthout complicationss in all animals. Coronary angiogra- 
phy was unchanged at 30 and 60 days. Serial LVEF in the treatment and control groups 
are shown in table l(a vs. b p=O.6; c vs.d p=O.5; e vs. f p= 0.02). 
Conclusion: These results suggest that MSC injection did not result in a marked inflam- 
matory response when compared to controls.lmprovement in LV function was shown in 
the MSC group as compared to controls. 
Comparison of LVEF m MSC vs. Control group 
MSCs (n=6) 
Control (n=6) 
Baseline 30 d after ameroid 60 d after ameroid / 
/before IMI 30 d after IMI 
55 * 7 (a) 43* 10 (C) 48?17 (s) 
56 f 8 (b) 37i 13 (d) 26*14(f) 
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